Enimmune Corporation (TPEX:6564)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
18.70
-0.65 (-3.36%)
Apr 29, 2026, 1:24 PM CST
-0.27%
Market Cap 1.37B
Revenue (ttm) 48.19M
Net Income (ttm) -164.35M
Shares Out 72.13M
EPS (ttm) -2.28
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 99,448
Average Volume 132,282
Open 19.35
Previous Close 19.35
Day's Range 18.60 - 19.35
52-Week Range 14.65 - 23.90
Beta 0.35
RSI 52.47
Earnings Date Aug 11, 2026

About Enimmune

Enimmune Corporation engages in the research, development, and sale of drugs in Taiwan. The company offers EnVAX-A71, AimFlu-S(QIS), tetanus vaccine adsorbed suspension for injection, COVID-19 Ag rapid test, vaccines, test reagents, and related western medicines, as well as biotechnology services. It is also involved in the development of vaccines for the prevention of infectious diseases, including pneumococcus, norovirus, dengue fever virus, and Middle East respiratory syndrome, such as cell culture-derived Japanese encephalitis vaccine, whic... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Employees 38
Stock Exchange Taipei Exchange
Ticker Symbol 6564
Full Company Profile

Financial Performance

In 2025, Enimmune's revenue was 48.19 million, an increase of 20.74% compared to the previous year's 39.92 million. Losses were -164.35 million, 4.32% more than in 2024.

Financial Statements

News

There is no news available yet.